1. Home
  2. REPX vs ANL Comparison

REPX vs ANL Comparison

Compare REPX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Riley Exploration Permian Inc.

REPX

Riley Exploration Permian Inc.

N/A

Current Price

$45.48

Market Cap

963.9M

Sector

Energy

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$15.99

Market Cap

998.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
REPX
ANL
Founded
2016
2004
Country
United States
Singapore
Employees
N/A
N/A
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
963.9M
998.8M
IPO Year
2003
2022

Fundamental Metrics

Financial Performance
Metric
REPX
ANL
Price
$45.48
$15.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
7
Target Price
★ $46.00
$29.50
AVG Volume (30 Days)
★ 252.7K
181.7K
Earning Date
11-04-2026
08-14-2026
Dividend Yield
★ 3.58%
N/A
EPS Growth
★ 78.17
N/A
EPS
★ 0.80
N/A
Revenue
★ $3,038,000.00
N/A
Revenue This Year
$52.25
$243.83
Revenue Next Year
$6.87
N/A
P/E Ratio
$55.80
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$24.08
$0.88
52 Week High
$45.31
$17.25

Technical Indicators

Market Signals
Indicator
REPX
ANL
Relative Strength Index (RSI) 69.75 57.29
Support Level $32.27 $14.70
Resistance Level N/A $17.10
Average True Range (ATR) 1.28 1.18
MACD 0.25 -0.10
Stochastic Oscillator 94.00 70.03

Price Performance

Historical Comparison
REPX
ANL

About REPX Riley Exploration Permian Inc.

Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations include: The Permian Basin is an oil and natural gas producing area located in West Texas.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: